Wednesday, April 09, 2025 CCTG related research presented at the ASCO GI Cancer Symposium, January 23-25, 2025 in San Francisco. CO28Loree JM, Titmuss E, Brown CJ, Rich TA, Tu D, Jonker DJ, O'Callaghan CJ, Kennecke HF. Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28). ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], 20-20. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.20 CRC5Battaglin F, Millstein J, Yang Y, Ashouri K, Soni S, Algaze S, Mittal P, Torres-Gonzalez L, Jayachandran P, Shah UH, Zhang W, Hochster HS, Ou F-S, Venook AP, Innocenti F, Finley SD, Lenz H-J. Impact of expression of metabolic genes on patient (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance). ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], 224-224. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.224 Mittal P, Yang Y, Ashouri K, Soni S, Battaglin F, Algaze S, Jayachandran P, Torres-Gonzalez L, Zhang W, Ou F-S, Venook AP, Millstein J, Lenz H-J. Impact of sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance). ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], 269-269. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.269 Ashouri K, Millstein J, Yang Y, Xiu J, Soni S, Jayachandran P, Mittal P, Algaze S, Torres-Gonzalez L, Shah UH, Shields AF, Goldberg RM, Lou E, Weinberg BA, Marshall J, Mumenthaler SM, Venook AP, Finley SD, Battaglin F, Lenz H-J. Clinical and molecular characterization of FAP and SPP1 in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data. ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], 276-276. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.276 CRC6Nowak JA, Shi Q, Twombly T, Pederson LD, Ma C, Väyrynen JP, Zhao MM, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler JP, Krishnamurthi SS, Tan BR, O'Reilly EM, Shields AF, Ogino S, Aleshin A, Meyerhardt JA. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], LBA14-LBA14. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.LBA14 CRC10Lieu CH, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America). ASCO Gastrointestinal Cancer Symposium. Journal of Clinical Oncology 43 [4_suppl], TPS310-TPS310. 2025.https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.4_suppl.TPS310